Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Nuclear reactors are ... produced by controlled fission chain reaction in nuclear reactors ... is used to drive a power- generating turbine. Currently ... the world’s total electricity production. Nuclear reactor market is ... construction, planned and proposed nuclear reactor projects. , Early ...
(Date:7/22/2014)... Rice Lake, Wisconsin (PRWEB) July 22, 2014 ... will be in attendance at the 2014 NCSL ... Florida. Booth #423 will feature CONDEC pressure ... balance style weights, and the new, customized sets, ... years ago to promote cooperative efforts in solving ...
(Date:7/22/2014)... Parsippany, NJ (PRWEB) July 22, 2014 ... analytical, precision, portable, and mechanical balances and scales, ... precision balances has won Laboratory Equipment magazine’s 2014 ... is the second consecutive year the Explorer was ... readers. The annual Readers’ Choice Awards celebrates “excellence ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... una filiale di BGI, la maggiore organizzazione di genomica ... nuovo servizio di sequenziamento dell,intero esoma umano con base ... Complete Genomics, molto apprezzata nel settore per ... con il 99.999% di precisione e una rilevazione altamente ...
Breaking Biology Technology:Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2
... 10 Endologix, Inc. (Nasdaq: ELGX ), developer of ... Lemaitre, former President and CEO of CoreValve, has joined the ... now has four independent directors and three non-independent directors. , ... pleased to welcome Dan Lemaitre to the Endologix Board of ...
... , ... signs of growth, Sidoti & Company, Wall Street,s largest, fastest-growing small cap ... unique investment opportunities within the micro cap market at the firm,s ... Grand Hyatt Hotel in New York, NY. , "Micro cap ...
... 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI ... identifies and advances a diverse portfolio of promising cancer-related products ... the proposed transaction which would result in the merger of ... October 5, 2009. The board of directors of Cytopia has ...
Cached Biology Technology:Endologix Appoints Dan Lemaitre to its Board of Directors 2Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4
(Date:7/22/2014)... allergic to dust mites (and chances are you are), ... the University of Iowa have developed a vaccine that ... immune response. In animal tests, the nano-sized vaccine package ... to the allergens, according to the paper, published in ... Journal . One big reason why it works, ...
(Date:7/22/2014)... An international collaboration known as the ,1000 Bull Genomes ... beef and dairy cattle while also improving animal health ... based on sequencing the whole genomes of 234 individual ... millions -- are reported in the journal Nature ... could use this information to reduce or eliminate hereditary ...
(Date:7/22/2014)... that split light with uncanny precision are key ... computers that manipulate light instead of electricity. But ... etching them with a precise beam of electrons, ... researchers at Princeton and Columbia universities have proposed ... customize and grow these specialized materials, known as ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Whole-genome sequencing of bulls in key beef and dairy breeds 2Technique simplifies the creation of high-tech crystals 2Technique simplifies the creation of high-tech crystals 3
... -- The Damon Runyon Cancer Research Foundation, a ... researchers and innovative cancer research, named 11 new ... Award Committee review. The recipients of this ... basic and translational cancer research in the laboratories ...
... just how big a carbon footprint is created by travel to ... kind in the world to look at this issue. It also ... as: Setting up audio/video facilities at airports ... to airports to see off friends and family., Situating luggage-drop facilities ...
... NARRAGANSETT, R.I. January 21, 2010 The bubbles ... and tickle your nose are exhibiting a behavior quite similar to ... physicist Helen Czerski. But while the champagne bubbles ... cause clouds to form and affect the climate. "Bubbles are ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 11 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 11 top young scientists 3Saying goodbye at airports the green way 2Bubble physicist counts bubbles in the ocean to answer questions about climate, sound, light 2Bubble physicist counts bubbles in the ocean to answer questions about climate, sound, light 3
SHP-2 Antibody...
Anti human PPAR gamma2 mouse monoclonal antibody...
... The antiserum has been tested on tissue ... staining pattern obtained with AB1773 corresponds to ... with probes to GLYT2 mRNA and to ... Preabsorption of the antiserum with the immunogen ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: